Sei Investments Co. Invests $62,000 in Actinium Pharmaceuticals, Inc. (NYSE:ATNM)

Sei Investments Co. purchased a new stake in Actinium Pharmaceuticals, Inc. (NYSE:ATNM) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 49,214 shares of the company’s stock, valued at approximately $62,000. Sei Investments Co. owned 0.16% of Actinium Pharmaceuticals as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in ATNM. Wellington Management Group LLP acquired a new position in Actinium Pharmaceuticals in the third quarter valued at about $112,000. Geode Capital Management LLC grew its position in shares of Actinium Pharmaceuticals by 3.0% in the 3rd quarter. Geode Capital Management LLC now owns 686,153 shares of the company’s stock valued at $1,290,000 after purchasing an additional 19,843 shares during the period. Barclays PLC grew its position in shares of Actinium Pharmaceuticals by 323.0% in the 3rd quarter. Barclays PLC now owns 42,935 shares of the company’s stock valued at $81,000 after purchasing an additional 32,784 shares during the period. Vontobel Holding Ltd. bought a new position in Actinium Pharmaceuticals in the fourth quarter valued at approximately $32,000. Finally, Los Angeles Capital Management LLC increased its position in shares of Actinium Pharmaceuticals by 25.0% during the fourth quarter. Los Angeles Capital Management LLC now owns 213,950 shares of the company’s stock worth $270,000 after acquiring an additional 42,770 shares in the last quarter. Institutional investors own 27.50% of the company’s stock.

Actinium Pharmaceuticals Stock Up 13.0 %

NYSE:ATNM opened at $1.30 on Friday. Actinium Pharmaceuticals, Inc. has a twelve month low of $1.03 and a twelve month high of $10.24. The firm has a market capitalization of $40.55 million, a price-to-earnings ratio of -0.94 and a beta of -0.27. The stock’s 50 day moving average price is $1.27 and its two-hundred day moving average price is $1.41.

Analysts Set New Price Targets

Several research firms have recently weighed in on ATNM. HC Wainwright reaffirmed a “buy” rating and set a $4.00 price objective on shares of Actinium Pharmaceuticals in a research report on Tuesday, April 1st. StockNews.com downgraded Actinium Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $7.40.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).